Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).


The pharmacokinetics of non-protein-bound platinum species derived from cis-dichlorodiammineplatinum(II) (cis-platinum) was studied under a variety of dosing conditions. Following rapid infusions (15-minute) of cis-platinum at 100 mg/m2, the unbound drug declined in a biphasic mode with a mean terminal half-life of 48 minutes. The mean beta-phase half-life after a 6-hour infusion of the same dose of cis-platinum was 26 minutes. Urinary excretion of filterable platinum was substantially greater after a 6-hour infusion than after a 15-minute injection. Concomitant administration of mannitol appeared to result in higher peak plasma concentrations and decreased urinary excretion of unbound platinum species but did not alter the terminal half-life. Renal impairment was associated with extremely high plasma levels of filterable platinum but did not affect other pharmacokinetic parameters. Preliminary data on the distribution of cis-platinum to ascitic fluid are also presented.

Citations per Year

6,040 Citations

Semantic Scholar estimates that this publication has 6,040 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Belt1979PharmacokineticsON, title={Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).}, author={Robert J. Belt and Kenneth J. Himmelstein and Thomas F. Patton and Steve J. Bannister and Larry A. Sternson and Arnold J. Repta}, journal={Cancer treatment reports}, year={1979}, volume={63 9-10}, pages={1515-21} }